BGES Bio Bridge Science Inc (CE)

Bio-Bridge Science, Inc. (OTCBB: BGES), a developer of vaccines with broad preventative and therapeutic applications, today announced that it has completed the major construction of a new state-of-the-art GMP research and manufacturing facility located in Beijing. The facility will provide a high quality research and production environment for the Company's vaccine products as well as pre-clinical and clinical trials. The first phase of the facility consists of an area 2,200 square meters, which includes the main facility, where research and production will take place. The research area consists of an 815 square meter clean air surface area. This area includes a 470 square meter 100,000 purity grade clean air environment, and a 345 square meter 10,000 purity grade clean air environment. There will also be several 100 purity grade clean air environments within the 10,000 purity grade area. The facility also includes a 750 square meter general working area and a 435 square meter electricity and water area. "We are pleased to have completed the initial stage of development for this state-of-the-art facility," said Bio-Bridge Science's CEO Dr. Liang Qiao. "This facility will allow us to produce the first HIV Vaccine in China, develop additional vaccines to cervical and colon cancers and to accelerate many of our promising research activities." The interior and exterior construction was completed according to GMP rules and requirements; however, construction of the high and low voltage electricity and installation of steam equipment is still taking place with local suppliers. About Bio-Bridge Science: Bio-Bridge Science is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Through its wholly owned subsidiary in Beijing, Bio-Bridge is developing a promising new HIV Vaccine that is expected to enter clinical trials this year in China. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an associate professor at Loyola University Chicago's Strich School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV. The Chinese government, mindful of the rapid expansion of AIDS in China has, through the "Green Mile Policy", acted to expedite the approval of domestically produced HIV Vaccines. Bio-Bridge Science's GMP facility will also be used to develop vaccines against cervical cancer and colon cancer under the same technology platform as the HIV vaccine. Forward Looking Statements This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to SEC filings for additional information and accompanying notes to financial statements.